Rivastigmine mini-tablet for Alzheimer's disease
Part of Brain & nervous system clinical trials.
This study tests whether a small, easy-to-swallow tablet of rivastigmine can help improve memory and thinking in people with moderate Alzheimer's disease. Rivastigmine is a common Alzheimer's medication that may help slow down memory loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years old or older.
- You have been diagnosed with probable Alzheimer's disease.
- You have moderate memory problems (scoring between 10 and 24 on a standard memory test).
- You are not severely depressed or having major psychiatric symptoms.
- A recent brain MRI shows no major strokes or severe white matter damage.
- You have a caregiver who is informed and preferably lives with you.
- You are not currently taking other dementia medications (must stop at least 2 weeks before starting).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether Huperzine A controlled-release tablets can help improve memory and thinking in people with mild-to-moderate Alzheimer's disease. You'll take the tablets or a placebo to see if it slows down dementia symptoms.
This trial tests if adding a rotigotine patch to your usual rivastigmine treatment can help with symptoms of Alzheimer's. It is for people with mild to moderate Alzheimer's who have been stable on rivastigmine for at least 3 months.
This Phase 2 trial tests an oral medicine (EX039) to see if it can help people with mild Alzheimer’s disease. It focuses on slowing or improving thinking and memory problems over time.
This study looks at how well people with Alzheimer’s disease (AD) or mild cognitive impairment (MCI) perform on standardized memory/brain tests. It may help researchers understand changes over time, and whether certain types of brain signals or test results track with the condition.
This trial compares donepezil (a medicine for Alzheimer’s symptoms) against a non-drug treatment plan. It aims to see which approach helps people with Alzheimer’s who still have measurable thinking ability and specific Alzheimer’s test results.
This trial tests a new drug, NBI-1117567, for people with mild to moderate Alzheimer's disease who are already taking a standard Alzheimer's medication. The goal is to see if the new drug can help improve symptoms.
Hear when a new Alzheimer's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.